Epoetin alfa: clinical trial therapy

Epoetin alfa is a glycoprotein with the same DNA structure and biological effects as endogenous erythropoietin. Clinical studies have demonstrated that Epoetin alfa effectively maintains RBC levels, decreases the need for transfusions, and improves the overall quality of life in anemic, ESRD, dialysis patients. The side-effect profile developed during the clinical trials reveals that Epoetin alfa is generally well tolerated.